glp 1 drugs history Market Overview: GLP-1 Agonists and the Obesity Market | Blog GLP-1 Agonists: A Comprehensive Overview
Description
Seven of these trials are expected to report results in 2026
The 2016 LEADER (NCT01179048) trial was the first to demonstrate a modest cardiovascular benefit in patients with T2D and stable cardiovascular disease receiving liraglutide, when compared to placebo
Small details, like clear timestamps and unambiguous policy language, often signal a platform that values its players
The exciting beyond obesity frontier for GLP-1 drugs is their potential to treat conditions where inflammation, or other non-obesity factors, are the primary cause
Employers are often focused on employee well-being, retention, and satisfaction
